Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study)

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1573-0646
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study) ; day:24 ; month:8 ; year:2020 ; pages:1-9
Investigational new drugs ; (24.8.2020), 1-9

Urheber
Yamashita, Toshinari
Kawaguchi, Hidetoshi
Masuda, Norikazu
Kitada, Masahiro
Narui, Kazutaka
Hattori, Masaya
Yoshinami, Tetsuhiro
Matsunami, Nobuki
Yanagihara, Kazuhiro
Kawasoe, Teru
Nagashima, Takeshi
Bando, Hiroko
Yano, Hiroshi
Hasegawa, Yoshie
Nakamura, Rikiya
Kashiwaba, Masahiro
Morita, Satoshi
Ohno, Shinji
Toi, Masakazu
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s10637-020-00991-6
URN
urn:nbn:de:101:1-2020101220012536393326
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:46 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Yamashita, Toshinari
  • Kawaguchi, Hidetoshi
  • Masuda, Norikazu
  • Kitada, Masahiro
  • Narui, Kazutaka
  • Hattori, Masaya
  • Yoshinami, Tetsuhiro
  • Matsunami, Nobuki
  • Yanagihara, Kazuhiro
  • Kawasoe, Teru
  • Nagashima, Takeshi
  • Bando, Hiroko
  • Yano, Hiroshi
  • Hasegawa, Yoshie
  • Nakamura, Rikiya
  • Kashiwaba, Masahiro
  • Morita, Satoshi
  • Ohno, Shinji
  • Toi, Masakazu
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer

Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer

Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel

Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel

Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pertuzumab/Trastuzumab (Mammakarzinom, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pertuzumab/Trastuzumab (Mammakarzinom, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V

Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)

Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)

Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)

Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients

Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients

Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China

Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China

Cost-Effectiveness Analysis of Adjuvant Pertuzumab and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer in Japan

Cost-Effectiveness Analysis of Adjuvant Pertuzumab and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer in Japan

Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)

Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)

Verbundene Objekte